Leukemia in infants

Oncologist

Volumn 4, Issue 3, 1999, Pages 225-240

  Felix, Carolyn A ^a,b   Lange, Beverly J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); Acute myeloid leukemia (AML); Clinical; Constitutional disorder; DNA topoisomerase II; Down syndrome; Epidemiology; MLL gene; Molecular biology

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; HYBRID PROTEIN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BRAIN RADIATION; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION 4; DRUG MEGADOSE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033023073     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-3-225     Document Type: Article

References (221)

1. Gibbons B, Katz FE, Ganly P et al. Infant acute lymphoblastic leukemia with t(11; 19). Br J Haematol 1990;74:264-279.
2. Ludwig WD, Bartram CR, Habott J et al. Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia 1989;3:431-439.
3. Arthur DC, Bloomfield CD, Lindquist LL et al. Translocation 4;11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance. Blood 1982;59:96-99.
4. Chessells JM, Eden OB, Bailey CC et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994;8:1275-1279.
5. Sorensen PH, Chen CS, Smith FO et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994;93:429-437.
6. Leiper AD, Chessells J. Acute lymphoblastic leukemia under age 2 years. Arch Dis Child 1986;61:1007-1012.
7. Cimino G, Lo Coco F, Biondi A et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993;82:544-546.
8. Pui C-H, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995;9:762-769.
9. Hilden JM, Frestedt JL, Moore RO et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23). Blood 1995;86:3876-3882.
10. Chen C-S, Sorensen PHB, Domer PH et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993;81:2386-2393.
11. Martinez-Climent JA, Thirman MJ, Espinosa R et al. Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis. Leukemia 1995;9:1299-1304.
12. Reaman G, Zeltzer P, Bleyer WA et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985;3:1513-1521.
13. Katz F, Malcolm S, Gibbons B et al. Cellular and molecular studies on infant null acute lymphoblastic leukemia. Blood 1988;71:1438-1447.
14. Reaman G, Sposto R, Sensel M et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999;17:445-455.
15. Winick N, McKenna RW, Shuster JJ et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993;11:209-217.
16. Pui C-H, Relling MV, Rivera GK et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995;9:1990-1996.
17. Smith MA, Rubenstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994;23:86-98.
18. Felix CA, Hosler MR, Winick NJ et al. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995;85:3250-3256.
19. Smith M, McCaffrey R, Karp J. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996;88:407-418.
20. Smith M, Rubenstein L, Anderson J et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577.
21. Corral J, Lavenir I, Impey H et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996;85:853-861.
22. Uckun FM, Herman-Hatten K, Crotty M-L et al. Clinical significance of MLL-AF-4 fusion transcript expression in absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 1998;92:810-821.
23. Gale K, Ford A, Repp R et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal bloodspots. Proc Natl Acad Sci USA 1997;94:13950-13954.
24. Rubnitz JE, Link MP, Shuster JJ et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994;84:570-573.
25. Chen C-S, Domer PH, Sorenson P et al. Highly clustered molecular rearrangements on chromosme 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1992;80(suppl 1):194a.
26. Heerema NA, Arthur DC, Sather H et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Children's Cancer Group. Blood 1994;83:2274-2284.
27. Pui C-H, Frankel LS, Carroll AJ et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991;77:440-447.
28. Behm FG, Raimondi SC, Frestedt JL et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996;87:2870-2877.
29. Crist W, Pullen J, Boyett J. Clinical and biologic features predict poor prognosis in acute lymphoblastic leukemia in infants. Blood 1986;67:135-140.
30. Pui C-H, Behm F, Downing J et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994;12:909-915.
31. So CW, Ma ZG, Price CM et al. MLL self fusion mediated by Alu repeat homologous recombination and prognosis of AML-M4/M5 subtypes. Cancer Res 1997;57:117-122.
32. Sandler ES, Friedman DJ, Mustafa MM et al. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997;79:1049-1054.
33. Gurney JG, Severson RK, Davis S et al. Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic types. Cancer 1995;75:2186-2195.
34. Pui C-H, Ribeiro RC, Campana D et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 1996;10:952-956.
35. Pui C-H, Raimondi SC, Murphy SB et al. An analysis of leukemic cell chromosomal features in infants. Blood 1987;69:1289-1293.
36. Ferster A, Bertrand Y, Benoit Y et al. Improved survival for lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994;86:284-290.
37. Lampert F, Harbott J, Ritterbach J. Cytogenetic findings in acute leukaemias of infants. Br J Cancer Suppl 1992;XVIII:S20-S22.
38. Cimino C, Rapanotti MC, LoCoco F et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 1995;9:391-395.
39. Haas OA. Cytogenetic abnormalities associated with childhood acute myeloblastic leukemia. Recent Results Cancer Res 1993;131:103-112.
40. Hilden JM, Frestedt JL, Kersey JH. Molecular analysis of infant acute leukemia. Leuk Lymphoma 1996;25:191-199.
41. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood 1995;85:1985-1999.
42. Luna-Fineman S, Shannon KM, Atwater SK et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999;93:459-466.
43. Arico M, Biondi A, Pui C-H. Juvenile myelomonocytic leukemia. Blood 1997;90:479-488.
44. Niemeyer CM, Arico M, Basso G et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997;89:3534-3543.
45. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down syndrome: a review. Pediatr Hematol Oncol 1987;4:211-230.
46. Bader-Meunier B, Mielot F, Tchernia G et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. French Society of Paediatric Haematology and Immunology. Br J Haematol 1996;92:344-350.
47. Mielot F, Bader-Meunier B, Tchernia G et al. Myelodysplasia in children and mitochondrial cytopathies. Pathol Biol (Paris) 1997;45:594-599.
48. Bader-Meunier B, Tchernia G, Mielot F et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997;130:885-889.
49. Ross JA, Davies SM, Potter JD et al. Epidemiology of childhood leukemia, with a focus on infants. Epidemiol Rev 1994;16:243-270.
50. Buckley JD, Robison LL, Swotinsky R et al. Occupational exposures of parents of children with acute nonlymphocytic leukemia: a report from the Children's Cancer Study Group. Cancer Res 1989;49:4030-4037.
51. Buckley JD. The aetiology of cancer in the very young. Br J Cancer Suppl 1992;XVIII:S8-S12.
52. Robison LL, Buckley JD, Daigle AE et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring: an epidemiologic investigation implicating marijuana (A report from the Children's Cancer Study Group). Cancer 1989;63:1904-1911.
53. Severson RK, Buckley JD, Woods WG et al. Cigarette smoking and alcohol consumption by parents of children with acute myeloid leukemia: an analysis within morphologic subgroups - a report from the Children's Cancer Group. Cancer Epidemiol Biomarkers Prev 1993;2:433-439.
54. van Duijin C, van Steensel-Moll H, Coebergh J-W et al. Risk factors for childhood acute non-lymphocytic leukemia: an association with maternal alcohol consumption during pregnancy? Cancer Epidemiol Biomarkers Prev 1994;3:457-460.
55. Shu X-O, Ross J, Pendergrass T et al. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Children's Cancer Group Study. J Natl Cancer Inst 1996;88:24-31.
56. Ross JA, Potter JD, Shu XO et al. Evaluating the relationships among maternal reproductive history, birth characteristics, and infant leukemia: a report from the Children's Cancer Group. Ann Epidemiol 1997;7:172-179.
57. Yeazel MW, Buckley JD, Woods WG et al. History of maternal fetal loss and increased risk of childhood acute leukemia at an early age: a report from the Children's Cancer Group. Cancer 1995;75:1718-1727.
58. Super HJG, McCabe NR, Thirman MJ et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA topoisomerase II. Blood 1993;82:3705-3711.
59. Corbett A, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993;6:585-597.
60. Ross JA, Potter JD, Reaman GH et al. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control 1996;7:581-590.
61. Reynolds T. Causes of childhood leukemia beginning to emerge. J Natl Cancer Inst 1998;90:8-10.
62. Setchell KD, Zimmer-Nechemias L, Cai J et al. Exposure of infants to photo-oestrogens from soy-based infant formula. Lancet 1997;350:23-27.
63. CDC. State-specific variation in rates of twin birth - United States, 1992-1994. MMWR 1997;46:121-125.
64. Buckley J, Buckley C, Breslow N et al. Concordance for childhood cancer in twins. Med Pediatr Oncol 1996;26:223-229.
65. Clarkson BD, Boyse EA. Possible explanation of the high concordance for acute leukaemia in monozygotic twins. Lancet 1971;1:699-701.
66. Zueler WW, Cox DE. Genetic aspects of leukemia. Semin Hematol 1969;6:228-249.
67. Ford AM, Ridge SA, Cabrera ME et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993;363:358-360.
68. Mahmoud HH, Ridge SA, Behm FG et al. Intrauterine monoclonal origin of neonatal concordant acute lymphoblastic leukemia in monozygotic twins. Med Pediatr Oncol 1995;24:77-81.
69. Gill-Super HJ, Rothberg PG, Kobayashi H et al. Clonal, non-constitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23. Blood 1994;83:641-644.
70. Bayar E, Kurczynski TW, Robinson MG et al. Monozygotic twins with congenital acute lymphoblastic leukemia (ALL) and t(4;11)(q21;q23). Cancer Genet Cytogenet 1996;89:177-180.
71. Megonigal MD, Rappaport EF, Jones DH et al. t(11;22)(q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc Natl Acad Sci USA 1998;95:6413-6418.
72. Hess JL, Yu BD, Li B et al. Defects in yolk-sac hematopoiesis in Mll-null embryos. Blood 1997;90:1799-1806.
73. Fidanza V, Melotti P, Yano T et al. Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res 1996;56:1179-1183.
74. Rasio D, Schichman SA, Negrini M et al. Complete exon structure of the ALL1 gene. Cancer Res 1996;56:1766-1769.
75. Djabali M, Selleri L, Parry P et al. A Trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias. Nat Genet 1992;2:113-118.
76. Tkachuk D, Kohler S, Cleary M. Involvement of a homolog of Drosophila Trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992;71:691-700.
77. Gu Y, Nakamura T, Alder H et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila Trithorax, to the AF-4 gene. Cell 1992;71:701-708.
78. Ma Q, Alder H, Nelson K et al. Analysis of the murine All-1 gene reveals conserved domains with human ALL-1 and identifies a motif shared with DNA methyltransferases. Proc Natl Acad Sci USA 1993;90:6350-6354.
79. Domer PH, Fakharzadeh SS, Chen C-S et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci USA 1993;90:7884-7888.
80. Yu BD, Hess JL, Horning SE et al. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995;378:505-508.
81. Gu Y, Cimino G, Alder H et al. The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc Natl Acad Sci USA 1992;89:10464-10468.
82. Negrini M, Felix CA, Martin C et al. Potential topoisomerase II DNA binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 1993;53:4489-4492.
83. Corral J, Forster A, Thompson S et al. Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation. Proc Natl Acad Sci USA 1993;90:8538-8542.
84. Gu Y, Alder H, Nakamura T et al. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res 1994;54:2327-2330.
85. Felix CA, Hosler MR, Slater DJ et al. MLL genomic break-point distribution within the breakpoint cluster region in de novo leukemia in children. J Pediatr Hematol Oncol 1998;20:299-308.
86. Cimino G, Rapanotti MC, Biondi A et al. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res 1997;57:2879-2883.
87. Megonigal MD, Rappaport EF, Jones DH et al. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci USA 1997;94:11583-11588.
88. Bernard O, Mauchauffe M, Mecucci C et al. A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL Oncogene 1994;9:1039-1045.
89. Nakamura T, Alder H, Gu Y et al. Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci USA 1993;90:4631-4635.
90. Rubnitz JE, Morrissey J, Savage PA et al. ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells. Blood 1994;84:1747-1752.
91. Prasad R, Gu Y, Alder H et al. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res 1993;53:5624-5628.
92. Thirman MJ, Levitan DA, Kobayashi H et al. Cloning of ELL, a gene that fuses to MIL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci USA 1994;91:12110-12114.
93. Tse W, Zhu W, Chen HS et al. A novel gene, AF1q, fused to MLL in t(1;11)(q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 1995;85:650-656.
94. Chaplin T, Bernard O, Beverloo HB et al. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 1995;86:2073-2076.
95. Chaplin T, Ayton P, Bernard OA et al. A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood 1995;85:1435-1441.
96. Parry P, Wei Y, Evans G. Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer 1994;11:79-84.
97. Taki T, Hayashi Y, Taniwaki M et al. Fusion of the MLL gene with two different genes, AF-6 and AF-5alpha, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia. Oncogene 1996;13:2121-2130.
98. Taki T, Sako M, Tsuchida M et al. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997;89:3945-3950.
99. Sobulo OM, Borrow J, Tomek R et al. MLL is fused to CBP, a histone acetyltransferase, in therapy related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 1997;94:8732-8737.
100. So C, Caldas C, Liu M-M et al. EEN encodes for a member of a new family of proteins containing a Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. Proc Natl Acad Sci USA 1997;99:2563-2568.
101. Hillion J, Le Coniat M, Jonveaux P et al. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a Forkhead transcriptional factor subfamily. Blood 1997;9:3714-3719.
102. Borkhardt A, Repp R, Haas O et al. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 1997;14:195-202.
103. Ida K, Kitabayashi I, Taki T et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 1997;90:4699-4704.
104. Taki T, Shibuya N, Taniwaki M et al. ABI-1, a human homolog to mouse Abl-1 interactor 1, fuses the MLL gene in acute myeloid leukemia with t(10;11)(p11.2;q23). Blood 1998;92:1125-1130.
105. Morrissey J, Tkachuk DC, Milatovich A et al. A serine/proline-rich protein is fused to HRX in t(4;11) acute leukemias. Blood 1993;81:1124-1131.
106. Chen CS, Medberry PS, Arthur D et al. Breakpoint clustering in t(4;11)(q21;q23) acute leukemias. Blood 1991;78:2498-2504.
107. Nilson I, Reichel M, Ennas MG et al. Exon/intron structure of the AF-4 gene, a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia. Br J Haematol 1997;98:157-169.
108. Felix C, Kim C, Megonigal M et al. Panhandle PCR amplifies genomic translocation breakpoint involving unknown partner gene. Blood 1997;90:4679-4686.
109. Felix CA, Jones DH. Panhandle PCR: a technical advance to amplify MLL genomic translocation breakpoints. Leukemia 1998;12:976-981.
110. Rowley JD, Reshmi S, Sobulo O et al. All patients with t(11;16)(q23;p13.3) that involve MLL and CBP have treatment-related hematologic disorders. Blood 1997;90:535-541.
111. Schichman SA, Caligiuri MA, Gu Y et al. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci USA 1994;91:6236-6239.
112. Caligiuri MA, Strout MP, Schichman SA et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996;56:1418-1425.
113. Yamamoto K, Hamaguchi H, Nagata K et al. Tandem duplication of the MLL gene in myelodysplastic syndrome-derived overt leukemia with trisomy 11. Am J Hematol 1997;55:41-45.
114. Yu M, Honoki K, Andersen J et al. MLL tandem duplication and multiple splicing in adult acute myeloid leukemia with normal karyotype. Leukemia 1996;10:774-780.
115. Schichman SA, Canaani E, Croce CM. Self-fusion of the ALL1 gene. JAMA 1995;273:571-576.
116. Downing JR, Head DR, Raimondi SC et al. The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood 1994;83:330-335.
117. Biondi A, Rambaldi A, Rossi V et al. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 1993;82:2943-2947.
118. Yamamoto K, Seto M, Iida S et al. A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemias with 11q23 abnormalities. Blood 1994;83:2912-2921.
119. Janssen JWG, Ludwig W-D, Borkhardt A et al. Pre-Pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL-1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 1994;84:3835-3842.
120. Wang JC. DNA topoisomerases. Ann Rev Biochem 1985;54:665-697.
121. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;84:191-218.
122. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation equilibrium of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989;28:6157-6160.
123. Chen GL, Yang L, Rowe TC et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:13560-13566.
124. Wang JC, Caron PR, Kim RA. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword? Cell 1990;62:403-406.
125. Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985;45:3106-3112.
126. Epstein RJ. Topoisomerases in human disease. Lancet 1988;1:521-524.
127. Osheroff N, Robinson MJ, Zechiedrich EL. Mechanism of the topoisomerase II-mediated DNA cleavage-religation reaction: inhibition of DNA religation by antineoplastic drugs. In: Potmesil M, Kohn K, eds. DNA Topoisomerases in Cancer. New York: Oxford University Press, 1991:230-239.
128. Felix CA, Lange BJ, Hosler MR et al. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 1995;55:4287-4292.
129. Barzilay G, Hickson ID. Structure and function of apurinic/ apyrimidinic endonucleases. Bioessays 1995;17:713-719.
130. Kingma P, Corbett A, Burcham P et al. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. J Biol Chem 1995;270:21441-21444.
131. Kingma P, Osheroff N. Apurinic sites are position-specific topoisomerase II poisons. J Biol Chem 1997;272:1148-1155.
132. Kingma P, Osheroff N. Spontaneous DNA damage stimulates topoisomerase II mediated DNA cleavage. J Biol Chem 1997;272:7488-7493.
133. Kingma PA, Greider CA, Osheroff N. Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochem 1997;36:5934-5939.
134. Reichel M, Gillert E, Nilson I et al. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 1998;17:3035-3044.
135. Lieber MR. The role of site-directed recombinases in physiologic and pathologic chromosomal rearrangements. In: Kirsch IR, ed. The Causes and Consequences of Chromosomal Aberrations. Boca Raton: CRC Press, 1993:239-275.
136. Atlas M, Head D, Behm F et al. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia 1998;12:1895-1902.
137. Stanulla M, Wang J, Chervinsky DS et al. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997;17:4070-4079.
138. Sim S-P, Liu LF. Cleavage within the breakpoint cluster region of the MLL gene induced by topoisomerase inhibitors. Proc AACR 1999;40:683.
139. Schnittger S, Wormann B, Hiddemann W et al. Partial tandem duplications of the MLL gene in peripheral blood and bone marrow of nearly all healthy donors. Blood 1998;92:1728-1734.
140. Lanza C, Gaidano G, Cimino G et al. p53 gene inactivation in acute lymphoblastic leukemia of B-cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. Leukemia 1995;9:955-959.
141. Lanza C, Gaidano G, Cimino G et al. Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer 1996;15:48-53.
142. Cimino G, Lanza C, Elia L et al. Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. Br J Haematol 1997;96:308-313.
143. Mahgoub N, Parker RI, Hosler MR et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer 1998;21:270-275.
144. Megonigal MD, Rappaport EF, Nowell PC et al. Potential role for wild-type p53 in leukemias with MLL gene translocations. Oncogene 1998;16:1351-1356.
145. Sun L, Heerema N, Crotty L et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1999;96:680-685.
146. Taki T, Ida K, Bessho F et al. Frequency and clinical significance of MLL gene rearrangements in infant acute leukemia. Leukemia 1996;10:1303-1307.
147. Matamores N, Matutes E, Hernandex N et al. Neonatal mixed lineage leukemia. Leukemia 1994;8:1236-1242.
148. Mirro J, Kitchingham G, Williams D et al. Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation. Blood 1986;67:689-697.
149. Wolk JA, Stuart MJ, Davey FR et al. Congenital and neonatal leukemia: lymphocytic or myelocytic? Am J Dis Child 1984;128:864-866.
150. Mirro J Jr, Kitchingman G, Behm FG et al. T-cell differentiation states identified by molecular and immunologic analysis of the T cell receptor complex in childhood lymphoblastic leukemia. Blood 1987;69:908-912.
151. Behm FG, Smith FO, Raimondi SC et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996;87:1134-1139.
152. Hilden JM, Smith FO, Frestedt JL et al. MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 1997;89:3801-3805.
153. Felix CA, Reaman G, Korsmeyer SJ et al. Immunoglobulin and T-cell receptor gene configuration in acute lymphoblastic leukemia of infancy. Blood 1987;70:536-541.
154. Felix CA, Poplack DG, Reaman GH et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990;8:431-442.
155. Raimondi SC, Peiper SC, Kitchingman GR et al. Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood 1989;77:1627-1634.
156. Huret JL, Brizard A, Slater R et al. Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients - updated published cases and 16 new observations. Leukemia 1993;7:152-160.
157. Morgan G, Cotter F, Katz F et al. Breakpoints at 11q23 in infant leukemia with the t(11;19)(q23;p13) are clustered. Blood 1992;80:2172-2175.
158. Rubnitz JE, Behm FG, Curcio-Brint AM et al. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood 1996;87:4804-4808.
159. Crist WM, Cleary ML, Grossi CE et al. Acute leukemias associated with the 4;11 chromosome translocations have rearranged immunoglobulin heavy chain genes. Blood 1985;66:33-38.
160. Felix CA, Wasserman R, Lange BJ et al. Differentiation stages of childhood acute lymphoblastic leukemias with p53 mutations. Leukemia 1994;8:963-967.
161. + B progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 1997;27:445-457.
162. Uckun FM, Sather HN, Gaynon PS et al. Clinical features and treatment outcomes in children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997;90:28-35.
163. Gaynon PS, Desai AA, Bostrom BC et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-1726.
164. Johansson B, Moorman AV, Haas OA et al. Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. Leukemia 1998;12:779-787.
165. Rubnitz JE, Camitta BM, Mahmoud H et al. Childhood acute lymphoblastic leukemia with MLL-ENL fusion and t(11;19)(q23;p13.3). J Clin Oncol 1999;17:191-196.
166. Kaleita T, MacLean W, Reaman G et al. Neurodevelopmental outcome of children diagnosed with ALL during infancy: a preliminary report from the Children's Cancer Study Group. SIOP XXIV Meeting Abstracts. Med Pediatr Oncol 1992:385a.
167. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood 1995;85:2354-2363.
168. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995;86:3247-3256.
169. Davies SM, Wagner JE, Weisdorf DJ. Unrelated donor bone marrow transplantation for hematological malignancies - current status. Leuk Lymphoma 1996;23:221-226.
170. Davies SM, Wagner JE, Shu XO et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997;15:557-565.
171. Beatty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993;81:249-253.
172. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-166.
173. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995;86:1228-1234.
174. Gluckman E, Rocha V, Boyer-Chamnard A et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337:373-381.
175. Wagner J, Kernan N, Steinbuch M et al. Allogeneic sibling umbilical cord blood transplantation in children with malignant and non malignant disease. Lancet 1995;1:214-219.
176. Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. N Engl J Med 1996;88:795-802.
177. Copelan EA, Deeg HH. Conditioning for allogeneic transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992;80:1648-1658.
178. Sanders JE. The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team. Semin Hematol 1991;28:244-249.
179. Johnson FL, Sanders JE, Ruggerio M et al. Bone marrow transplantation for the treatment of acute non-lymphoblastic leukemia in children aged less than 2 years. Blood 1988;71:1277-1280.
180. Kaleita TA, Shields WD, Tesler A et al. Normal neurodevelopment in four young children treated with bone marrow transplantation for acute leukemia or aplastic anemia. Pediatrics 1989;83:753-757.
181. Sanders JE. Bone marrow transplantation for pediatric malignancies. Pediatr Clin North Am 1997;44:1005-1020.
182. Dreyer ZE, Steuber CP, Bowman WP et al. Induction intensification for infant acute lymphoid leukemia (ALL). Proc Am Soc Clin Oncol 1996;15:1094a.
183. Stanulla M, Schunemann HJ, Thandla S et al. Pseudorearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients. J Clin Pathol: Mol Pathol 1998;51:85-89.
184. Pui C-H, Kalwinsky DK, Schell MJ et al. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol 1988;6:1008-1013.
185. Lampkin BC. The newborn infant with leukemia. J Pediatr 1997;131:176-177.
186. Grier HH, Gelber RD, Camitta BM et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987;5:1026-1032.
187. Smith FO, Lampkin BC, Versteeg C et al. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic
188. Griffin JD, Larcom P, Schlossman SF. Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. Blood 1983;62:1300-1303.
189. Barnard DR, Kalousek DK, Wiersma SR et al. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: a report from the Children's Cancer Group. Leukemia 1996;10:5-12.
190. Smith FO, Raskind WH, Fialkow PJ et al. Cellular biology of acute myelogenous leukemia. J Pediatr Hematol Oncol 1995;17:113-122.
191. Kalwinsky DK, Raimondi SC, Shell MJ et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990;8:75-83.
192. Woods WG, Nesbit ME, Buckley J et al. Correlation of chromosome abnormalities with patient characteristics, histologic subtype and induction success in children with acute non-lymphocytic leukemia. J Clin Oncol 1985;3:3-11.
193. Kaneko Y, Rowley JD, Mauer HS et al. Chromosome pattern in childhood acute nonlymphocytic leukemia (ANLL). Blood 1982;60:389-399.
194. Tivey H. The natural history of untreated acute leukemia. Ann NY Acad Sci 1954;60:322.
195. Van Eys J, Flexner JM. Transient spontaneous remission in a case of untreated congenital leukemia. Am J Dis Child 1969;118:507-514.
196. Lilleyman JS. Congenital monocytic leukemia. Clin Lab Haematol 1980;2:243-245.
197. Pierce MI. Leukemia in the newborn infant. J Pediatr 1959;54:691-706.
198. Lampkin BC, Peipon JJ, Price JK et al. Spontaneous remission of presumed congenital acute nonlymphoblastic leukemia (ANLL) in a karyotypically normal neonate. Am J Pediatr Hematol Oncol 1985;7:346-351.
199. Dinulos J, Hawkins D, Clark B et al. Spontaneous remission of congenital leukemia. J Pediatr 1977;131:300-303.
200. Bader JL, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr 1978;92:925-929.
201. Shannon K, O'Connell P, Martin G et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
202. Passmore SJ, Hann IM. Paediatric myelodysplasia. Br Med Bull 1996;52:778-786.
203. Hurwitz CA, Schell JJ, Pui C-H et al. Adverse prognostic features in 251 children treated for acute myeloid leukemia. Med Pediatr Oncol 1993;21:1-7.
204. Smith FO, Howells WB, Buckely JD et al. Prognostic factors (PF) in children with acute myeloid leukemia (AML): results of Children's Cancer Group (CCG) protocol 2891. Blood 1997;90(suppl 1):561a.
205. Smith FO, Rauch C, Williams DE et al. The human homologue of rat NG2, a chondroidn sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996;87:1123-1133.
206. Martinez-Climent JA, Espinosa R, Thirman MJ et al. Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. J Pediatr Hematol Oncol 1995;17:277-283.
207. Creutzig U, Harbott J, Sperling C et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995;86:3097-3108.
208. LeBlanc T, Auvirignon A, Michel G et al. Prognostic value of cytogenetics in 250 children with acute myeloblastic leukemia treated in the LAME 89/91 protocol. Blood 1996;88S1:634a.
209. Swansbury GJ, Slater R, Bain BJ et al. Hematological malignancies with t(9;11)(p21-22;q23) - a laboratory study of 125 cases. Leukemia 1998;12:792-800.
210. Moorman AV, Hagemeijer A, Charrin C et al. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. Leukemia 1998;12:805-810.
211. Martineau M, Berger R, Lillington DM et al. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. Leukemia 1998;12:788-791.
212. Lillington DM, Young BD, Berger R et al. The t(10;11)(p12;q23) translocation in acute leukemia: a cytogenetic and clinical study of 20 patients. Leukemia 1998;12:801-804.
213. Wells RJ, Woods WG, Buckley JD et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children's Cancer Group Study. J Clin Oncol 1994;12:2367-2377.
214. Woods WG, Kobrinsky N, Buckley JD et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996;87:4979-4989.
215. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myeloid leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990;75:1932-1942.
216. Michel G, Baruchel A, Tabone MD et al. Induction chemotherapy followed by allogeneic marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther 1996;38:169-176.
217. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428-1434.
218. Lie SO, Jonmundsson G, Mellander L et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996;94:82-88.
219. Hann IM, Stevens RF, Goldstone AH et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311-2318.
220. Odom LF, Gordon EM. Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. Blood 1984;64:875-882.
221. Woolfrey AE, Gooley TA, Sievers EL et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 1998;92:3546-3556.